{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:18:12Z","timestamp":1792293492905,"version":"4.4.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Radiochemotherapy (RCHT) for the treatment of anal squamous cell carcinoma (ASCC) has evolved dramatically, also thanks to intensity-modulated RT (IMRT) and 3D image guidance (3D IGRT). Despite most patients presenting fair outcomes, unmet needs still exist. Predictors of poor tumor response are lacking; acute toxicity remains challenging; and local relapse remains the main pattern of failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Between 2010 and 2020, ASCC stages I\u2013III treated with 3D conformal radiotherapy or IMRT and CDDP-5FU or Mytomicine-5FU CHT were identified. Image guidance accepted included 2D IGRT or 3D IGRT. The study endpoints included freedom from locoregional recurrence (FFLR), colostomy free survival (CFS), freedom from distant metastasis (FFDM), overall survival (OS), and acute and late toxicity as measured by common terminology criteria for adverse events (CTCAE) version 5.0. An exploratory analysis was performed to identify possible radiomic predictors of tumor response. Feature extraction and data analysis were performed in Python\u2122, while other statistics were performed using SPSS<jats:sup>\u00ae<\/jats:sup> v.26.0 software (IBM<jats:sup>\u00ae<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 131 patients were identified. After a median FU of 52 months, 83 patients (63.4%) were alive. A total of 35 patients (26.7%) experienced locoregional failure, while 31 patients (23.7%) relapsed with distant metastasis. Five year FFLR, CFS, DMFS and PS resulted 72.3%, 80.1%, 74.5% and 64.6%. In multivariate analysis, 2D IGRT was associated with poorer FFLR, OS, and CFS (HR 4.5, 4.1, and 5.6, respectively); 3DcRT was associated with poorer OS and CFS (HR 3.1 and 6.6, respectively). IMRT reduced severe acute gastro-intestinal (GI) and severe skin acute toxicity in comparison with 3DcRT. In the exploratory analysis, the risk of relapse depended on a combination of three parameters: Total Energy, Gray Level Size Zone Matrix\u2019s Large Area High Gray Level Emphasis (GLSZM\u2019s LAHGLE), and GTV volume.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Advances in radiotherapy have independently improved the prognosis of ASCC patients over years while decreasing acute GI and skin toxicity. IMRT and daily 3D image guidance may be considered standard of care in the management of ASCC. A combination of three pre-treatment MRI parameters such as low signal intensity (SI), high GLSZM\u2019s LAHGLE, and GTV volume could be integrated in risk stratification to identify candidates for RT dose-escalation to be enrolled in clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.973223","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T06:28:55Z","timestamp":1666592935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Marco Lorenzo","family":"Bon\u00f9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"La Mattina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Toraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Spiazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Terraneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Guerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Imbrescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Andreuccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Frittoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Pittiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Grazioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazario","family":"Portolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano Maria","family":"Magrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Buglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199403000-00001","article-title":"Anal human papillomavirus infection and anal cancer in hiv-positive individuals: An emerging problem","volume":"8","author":"Palefsky","year":"1994","journal-title":"AIDS"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz329","article-title":"North American ACCoR and design of the international epidemiologic databases to evaluate a: Association of immunosuppression and human immunodeficiency virus (hiv) viremia with anal cancer risk in persons living with hiv in the united states and canada","volume":"70","author":"Hernandez-Ramirez","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of us gi intergroup rtog 98-11 phase iii trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: Esmo-esso-estro clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (act ii): A randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-term outcomes of nrg oncology\/rtog 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2011.01.015","article-title":"Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment","volume":"201","author":"Eeson","year":"2011","journal-title":"Am J Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9491-8","article-title":"Outcomes of salvage surgery for squamous cell carcinoma of the anal canal","volume":"14","author":"Schiller","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4908","article-title":"Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer","volume":"92","author":"Renehan","year":"2005","journal-title":"Br J Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9221-7","article-title":"Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal","volume":"14","author":"Mullen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase ii trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: Interaact","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.01.022","article-title":"Mri heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer","volume":"134","author":"Owczarczyk","year":"2019","journal-title":"Radiother Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal trials group (agitg) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/wics.101","article-title":"Principal component analysis","volume":"2","author":"Abdi","year":"2010","journal-title":"WIREs Comput Stat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/B:STCO.0000035301.49549.88","article-title":"A tutorial on support vector regression","volume":"14","author":"Smola","year":"2004","journal-title":"Stat Computing"},{"key":"B19","unstructured":"Machine learning in python2012"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v086.i08","article-title":"Image segmentation, registration and characterization in r with simpleitk","volume":"86","author":"Beare","year":"2018","journal-title":"J Stat Softw"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.15.2348","article-title":"Hiv-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of hiv-positive patients receiving highly active antiretroviral therapy","volume":"26","author":"Oehler-J\u00e4nne","year":"2008","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.radonc.2010.11.011","article-title":"Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin c for anal carcinoma: Are there differences between hiv-positive and hiv-negative patients in the era of highly active antiretroviral therapy","volume":"98","author":"Fraunholz","year":"2011","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30440-0","article-title":"Radiotherapy in patients with hiv: Current issues and review of the literature","volume":"18","author":"Alongi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050427","article-title":"Concurrent chemoradiation in anal cancer patients delivered with bone marrow-sparing imrt: Final results of a prospective phase ii trial","volume":"11","author":"Arcadipane","year":"2021","journal-title":"J Pers Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.12.022","article-title":"Uk national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes","volume":"128","author":"Gilbert","year":"2020","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-020-03517-x","article-title":"Intensity-modulated radiotherapy (imrt) in the treatment of squamous cell anal canal cancer: Acute and early-late toxicity, outcome, and efficacy","volume":"35","author":"Dell'Acqua","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.008","article-title":"Change in t2-fat saturation mri correlates with outcome in cervical cancer patients","volume":"81","author":"Ma","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13014-019-1262-8","article-title":"A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy","volume":"14","author":"Jadon","year":"2019","journal-title":"Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12885-015-1244-7","article-title":"Multiparametric mri as an outcome predictor for anal canal cancer managed with chemoradiotherapy","volume":"15","author":"Jones","year":"2015","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081791","article-title":"Mr-Guided hypofractionated radiotherapy: Current emerging data and promising perspectives for localized prostate cancer","volume":"13","author":"Cuccia","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.973223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T06:28:59Z","timestamp":1666592939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.973223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":31,"alternative-id":["10.3389\/fonc.2022.973223"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.973223","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"article-number":"973223"}}